Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Given Average Recommendation of “Hold” by Analysts

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) has been given a consensus rating of “Hold” by the six ratings firms that are presently covering the company, MarketBeat Ratings reports. Two research analysts have rated the stock with a sell rating and four have assigned a buy rating to the company. The average 1-year target price among brokers that have updated their coverage on the stock in the last year is $16.57.

Several equities analysts have recently issued reports on the stock. Canaccord Genuity Group boosted their price target on shares of Y-mAbs Therapeutics from $22.00 to $26.00 and gave the company a “buy” rating in a report on Monday, March 4th. Wedbush reaffirmed an “outperform” rating and issued a $18.00 price objective (up previously from $12.00) on shares of Y-mAbs Therapeutics in a report on Monday, February 12th. BMO Capital Markets raised their target price on shares of Y-mAbs Therapeutics from $16.00 to $26.00 and gave the company an “outperform” rating in a research note on Monday, March 4th. Finally, HC Wainwright boosted their price target on shares of Y-mAbs Therapeutics from $21.00 to $22.00 and gave the stock a “buy” rating in a research report on Wednesday, March 6th.

Insiders Place Their Bets

In other news, SVP Vignesh Rajah sold 1,711 shares of the stock in a transaction on Tuesday, March 5th. The stock was sold at an average price of $16.53, for a total value of $28,282.83. Following the completion of the sale, the senior vice president now owns 33,889 shares in the company, valued at $560,185.17. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Corporate insiders own 21.50% of the company’s stock.

Institutional Trading of Y-mAbs Therapeutics

A number of hedge funds have recently made changes to their positions in the stock. Polar Capital Holdings Plc increased its stake in Y-mAbs Therapeutics by 108.9% in the 1st quarter. Polar Capital Holdings Plc now owns 2,877,671 shares of the company’s stock valued at $34,187,000 after buying an additional 1,500,000 shares during the period. Millennium Management LLC grew its stake in Y-mAbs Therapeutics by 4,676.0% in the fourth quarter. Millennium Management LLC now owns 1,128,702 shares of the company’s stock valued at $5,508,000 after purchasing an additional 1,105,069 shares in the last quarter. State Street Corp increased its stake in shares of Y-mAbs Therapeutics by 58.5% during the 1st quarter. State Street Corp now owns 2,308,782 shares of the company’s stock worth $27,428,000 after purchasing an additional 852,112 shares during the last quarter. AQR Capital Management LLC acquired a new position in shares of Y-mAbs Therapeutics during the 4th quarter worth $2,343,000. Finally, Point72 Asset Management L.P. bought a new position in shares of Y-mAbs Therapeutics during the 4th quarter valued at $2,193,000. 70.85% of the stock is owned by hedge funds and other institutional investors.

Y-mAbs Therapeutics Price Performance

Y-mAbs Therapeutics stock opened at $14.07 on Wednesday. Y-mAbs Therapeutics has a 12 month low of $4.60 and a 12 month high of $20.90. The company has a fifty day moving average price of $15.54 and a two-hundred day moving average price of $9.70. The company has a market cap of $615.98 million, a PE ratio of -28.71 and a beta of 0.74.

Y-mAbs Therapeutics (NASDAQ:YMAB) last issued its earnings results on Thursday, February 29th. The company reported ($0.02) EPS for the quarter, beating analysts’ consensus estimates of ($0.19) by $0.17. The company had revenue of $23.36 million during the quarter, compared to the consensus estimate of $21.72 million. Y-mAbs Therapeutics had a negative return on equity of 20.72% and a negative net margin of 25.26%. Equities research analysts anticipate that Y-mAbs Therapeutics will post -0.43 earnings per share for the current year.

About Y-mAbs Therapeutics

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.